Oncology focused biotech to utilise 4basebio’s opDNA® technology to support Phase II clinical trial of immunotherapy candidate Multi-year, ...

The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not ...

Richard Bungay appointed as CFO, bringing a strong track record in fundraising, M&A and partnering for listed and private companies, ...

Insiders were net buyers of 4basebio PLC's (LON:4BB ) stock during the past year. That is, insiders bought more stock than they sold. While insider transactions are not the most important thing when ...

Wednesday that it had signed a clinical supply agreement with a cancer immunotherapy company to provide GMP-grade opDNA ...

CAMBRIDGE, England, July 01, 2025--(BUSINESS WIRE)--4basebio PLC (AIM: 4BB) ("4basebio"), a specialist in synthetic DNA manufacturing and nucleic acids for next-generation therapeutics, today ...

Seasoned biotechnology commercial leader will drive global growth strategy Commercial team further bolstered by promotions of James Vang and Jennifer Gelman to VP, Business Development and VP, ...

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL ...

4basebio PLC Annual stock financials by MarketWatch. View the latest 4BB financial statements, income statements and financial ratios.